로딩 중…
지수 로딩 중…
Phathom Pharmaceuticals, Inc.
PHAT· NASDAQ· Health Care· Pharmaceuticals, Biotechnology & Life Sciences
$8.98+2.63%
2026-08-03
Financials
Valuation Metrics
Phathom Pharmaceuticals, Inc.'s Market Cap is $716M. At end of 2025 it was $1.21B. Ranked #2651 of 3,112 in US market (top 85%), #1124 of 1,445 on NASDAQ (top 78%), #210 of 269 in Pharmaceuticals, Biotechnology & Life Sciences (top 78%) by Market Cap.
Investment Metrics(as of 2026-08-03)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $716M | US#2,651/3,112 Sec#210/269 |
| Revenue | $240M | US#2,635/3,112 Sec#104/269 |
| Net Income | $-81M | US—/3,112 Sec—/269 |
| Total Assets | $327M | US#2,873/3,112 Sec#200/269 |
| Net Assets | $72M | US#2,910/3,112 Sec#236/269 |
| Value | ||
| P/B | 9.93x | US#2,611/3,112 Sec#203/269 |
| P/S | 2.99x | US#1,750/3,112 Sec#47/269 |
| FCF Yield | -5.11% | US—/3,112 Sec—/269 |
| Profitability | ||
| ROE | -112.94% | US#2,866/3,112 Sec#224/269 |
| ROA | -24.91% | US#2,826/3,112 Sec#144/269 |
| Op. Margin | -16.96% | US#2,683/3,112 Sec#105/269 |
| Revenue Growth | 88.02% | US#171/3,112 Sec#36/269 |
| Financial Health | ||
| Debt Ratio | 930.41% | US#2,742/3,112 Sec#242/269 |
| Total Debt | $3M | US#2,897/3,112 Sec#233/269 |
| FCF | $-37M | US#2,438/3,112 Sec#107/269 |
| Cash | $182M | US#1,794/3,112 Sec#122/269 |
| Current Ratio | 1.92x | US#1,297/3,112 Sec#231/269 |
| Performance | ||
| 1Y Return | 7.54% | US#1,944/3,112 Sec#186/269 |
| 1M Return | -19.82% | US#2,944/3,112 Sec#234/269 |
| From 52W High | -50.96% | US#2,801/3,112 Sec#221/269 |
| 1Y MDD | -51.60% | US#2,464/3,112 Sec#190/269 |
| Trading | ||
| Volume | 1,520,299 shares | US#1,108/3,112 Sec#104/269 |
| Trading Value | $14M | US#2,185/3,112 Sec#170/269 |
| Per Share | ||
| EPS | $-3.03 | US—/3,112 Sec—/269 |